A groundbreaking trial for a new drug shows promise in eliminating a type of cancer that is on the rise among young adults. Bowel cancer, known for its elusive symptoms that complicate diagnosis, claims nearly 17,000 lives annually in the UK and is increasingly affecting individuals under 50 years old. The ongoing NHS trial, which gained attention following the passing of TV presenter Dame Deborah James in 2022 at the age of 40, has brought hope through a novel approach to treatment.
Nick Cleworth, a 48-year-old train driver, shared his success story after his golf ball-sized tumor was successfully treated with an innovative immunotherapy drug, palupiprant. Unlike traditional surgical methods that could have resulted in a colostomy bag, Nick’s tumor was eradicated through a combination of palupiprant, standard chemotherapy, and radiotherapy as part of a trial involving 140 patients across 22 NHS facilities. This drug triggers the body’s immune system to fight cancer cells effectively.
The rise of early-onset bowel cancer, especially among individuals aged 25 to 49 in England, has prompted further investigation into contributing factors such as poor diet, increased consumption of ultra-processed foods, obesity, and lack of physical activity. Nick, who had a family history of the disease, was vigilant about his health and sought medical attention promptly when he noticed concerning symptoms. Following a diagnosis of rectal cancer with lymph node involvement, Nick enrolled in the ARTEMIS trial, a phase II study aimed at assessing the efficacy of palupiprant in treating rectal cancer.
Under the care of Dr. Claire Arthur at The Christie NHS Foundation Trust in Manchester, Nick received hopeful news of his eligibility for the trial, which ultimately led to his cancer-free status following successful treatment. Dr. Arthur emphasized the significance of immunotherapy in cancer treatment, highlighting its potential in leveraging the body’s immune response against cancer cells. The positive outcomes observed in Nick’s case underscore the importance of ongoing research to enhance treatment approaches for rectal cancer.
As clinical trials like ARTEMIS progress through various phases to evaluate the safety and effectiveness of new drugs, the medical community remains dedicated to advancing cancer care. By engaging more patients in trials like ARTEMIS, researchers aim to validate promising findings and potentially revolutionize the standard of care for rectal cancer within the NHS. Through initiatives like the Be Part of Research program, individuals can express interest in participating in clinical trials and contribute to advancements in cancer treatment.
If you are interested in participating in clinical trials or learning more about research opportunities, you can register for the Be Part of Research initiative by clicking HERE.